{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:47:13Z","timestamp":1761763633430},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6658,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1023\/a:1012599307090","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T13:43:47Z","timestamp":1040651027000},"page":"1417-1422","source":"Crossref","is-referenced-by-count":29,"title":["Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group"],"prefix":"10.1016","volume":"12","author":[{"given":"D.","family":"Pectasides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kiamouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bafaloukos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Xiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Visvikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1012599307090_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3322\/canjclin.45.1.8","article-title":"Cancer Statistics 1995","volume":"45","author":"Wingo","year":"1995","journal-title":"CA Cancer J Clin"},{"key":"10.1023\/A:1012599307090_bb0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","article-title":"Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic cell carcinoma of the urinary tract. A Northern California Oncology Group Study","volume":"3","author":"Harker","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(17)42494-3","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium","volume":"341","author":"Stenberg","year":"1988","journal-title":"J Urol"},{"key":"10.1023\/A:1012599307090_bb0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/oxfordjournals.annonc.a058775","article-title":"Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study","volume":"5","author":"Pollera","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1012599307090_bb0030","first-page":"246","article-title":"Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cancer","volume":"15","author":"De Luna","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0035","first-page":"230","article-title":"Ifosfamide in advanced urothelial carcinoma. An ECOG trial","volume":"13","author":"Witte","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0040","first-page":"459","article-title":"Clinical evaluation of Z 4942 (ifosfamide) for malignant urological tumors","volume":"27","author":"Otarugo","year":"1981","journal-title":"Hinyokika Kiyo"},{"key":"10.1023\/A:1012599307090_bb0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0090-4295(91)80152-W","article-title":"Gallium nitrate in advanced bladder carcinoma. A Southwest Oncology Group Study","volume":"38","author":"Crawford","year":"1991","journal-title":"Urology"},{"key":"10.1023\/A:1012599307090_bb0050","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jnci\/83.21.1582","article-title":"Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate","volume":"83","author":"Seligman","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1012599307090_bb0055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/1097-0142(19911215)68:12<2561::AID-CNCR2820681205>3.0.CO;2-G","article-title":"Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors","volume":"68","author":"Sedman","year":"1991","journal-title":"Cancer"},{"key":"10.1023\/A:1012599307090_bb0060","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/1097-0142(19940201)73:3<688::AID-CNCR2820730330>3.0.CO;2-V","article-title":"Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma","volume":"73","author":"Witte","year":"1994","journal-title":"Cancer"},{"key":"10.1023\/A:1012599307090_bb0065","first-page":"202","article-title":"The activity of antimicrotubular agents in human bladder tumor cell lines","volume":"34","author":"Niel","year":"1993","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1023\/A:1012599307090_bb0070","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","article-title":"Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E 1892)","volume":"12","author":"Roth","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0075","first-page":"5","article-title":"Phase II study of docetaxel (Taxotere) in patients with metastatic urothelial cancer","volume":"12","author":"De Wit","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1012599307090_bb0080","first-page":"233","article-title":"Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin-based chemotherapy. A phase II trial","volume":"14","author":"McCaffrey","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0085","first-page":"137","article-title":"Epirubicin, ifosfamide combination chemotherapy in invasive bladder cancer","volume":"9","author":"Nazli","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0090","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadrel","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0095","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"A promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1012599307090_bb0105","series-title":"WHO Handbook for Reporting Results of Cancer Treatment. No 48","year":"1979"},{"key":"10.1023\/A:1012599307090_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1023\/A:1012599307090_bb0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1997.15.2.589","article-title":"Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma","volume":"15","author":"White","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1012599307090_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0959-8049(93)90197-N","article-title":"Feasibility trial of a combination of vinorelbine, ifosfamide, fluoruracil and folonic acid (VIF regimen) in advanced urothelial cancer","volume":"29A","author":"Mahjoubi","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1012599307090_bb0125","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.1994.12.11.2271","article-title":"Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial cancer","volume":"12","author":"Einhorn","year":"1994","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1023\/A:1012599307090_bb0130","first-page":"S36","article-title":"A phase II trial of gemcitabine and ifosfamide in non-small-cell lung cancer","volume":"24","author":"Gatzemeier","year":"1997","journal-title":"Semin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419543368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419543368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/10\/1417\/19478834\/12-10-1417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:09:04Z","timestamp":1582182544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419543368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S0923753419543368"],"URL":"https:\/\/doi.org\/10.1023\/a:1012599307090","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}